002317 众生药业
交易中 06-24 13:37:51
资讯
新帖
简况
众生药业涨9.99%,开源证券一个月前给出“买入”评级
证券之星 · 06-18
众生药业涨9.99%,开源证券一个月前给出“买入”评级
6月18日众生药业(002317)涨停分析:减肥药、MASH创新药、流感药驱动
证券之星 · 06-18
6月18日众生药业(002317)涨停分析:减肥药、MASH创新药、流感药驱动
众生药业(002317)披露使用闲置自有资金进行委托理财的进展公告,6月17日股价下跌4.71%
证券之星 · 06-17
众生药业(002317)披露使用闲置自有资金进行委托理财的进展公告,6月17日股价下跌4.71%
众生药业:昂拉地韦片是全球首款靶向甲型流感病毒RNA聚合酶PB2亚基的一类创新药
证券之星 · 06-17
众生药业:昂拉地韦片是全球首款靶向甲型流感病毒RNA聚合酶PB2亚基的一类创新药
众生药业:RAY1225注射液表现出积极的疗效和优秀的安全性
证券之星 · 06-11
众生药业:RAY1225注射液表现出积极的疗效和优秀的安全性
众生药业:RAY1225注射液III期临床试验于2025年7月完成入组工作
证券之星 · 06-11
众生药业:RAY1225注射液III期临床试验于2025年7月完成入组工作
众生药业:公司积极推进与监管部门的沟通
证券之星 · 06-11
众生药业:公司积极推进与监管部门的沟通
众生药业:积极参与美国糖尿病协会科学年会会议
证券之星 · 06-04
众生药业:积极参与美国糖尿病协会科学年会会议
众生药业(002317.SZ):昂拉地韦颗粒纳入优先审评品种名单
智通财经 · 06-02
众生药业(002317.SZ):昂拉地韦颗粒纳入优先审评品种名单
众生药业:ZSP1601片Ib/IIa期临床试验结果已发表在自然杂志子刊《Nature Communications》
证券之星 · 05-28
众生药业:ZSP1601片Ib/IIa期临床试验结果已发表在自然杂志子刊《Nature Communications》
华鑫证券:给予众生药业买入评级
证券之星 · 05-28
华鑫证券:给予众生药业买入评级
众生药业:公司正在积极推进RAY1225注射液的III期临床试验
证券之星 · 05-27
众生药业:公司正在积极推进RAY1225注射液的III期临床试验
众生药业:昂拉地韦片是全球首款靶向甲型流感病毒RNA聚合酶PB2亚基的一类创新药
证券之星 · 05-27
众生药业:昂拉地韦片是全球首款靶向甲型流感病毒RNA聚合酶PB2亚基的一类创新药
众生药业:公司立足自身产品优势与研发实力,坚持稳健布局、审慎推进的原则,适时拓展海外市场,加快国际化推进步伐
证券之星 · 05-26
众生药业:公司立足自身产品优势与研发实力,坚持稳健布局、审慎推进的原则,适时拓展海外市场,加快国际化推进步伐
众生药业(002317)披露2025年年度权益分派实施公告,5月25日股价下跌0.88%
证券之星 · 05-25
众生药业(002317)披露2025年年度权益分派实施公告,5月25日股价下跌0.88%
【机构调研记录】惠升基金调研众生药业
证券之星 · 05-21
【机构调研记录】惠升基金调研众生药业
股市必读:众生药业(002317)5月20日董秘有最新回复
证券之星 · 05-21
股市必读:众生药业(002317)5月20日董秘有最新回复
众生药业:昂拉地韦片是全球首款靶向甲型流感病毒RNA聚合酶PB2亚基的一类创新药
证券之星 · 05-20
众生药业:昂拉地韦片是全球首款靶向甲型流感病毒RNA聚合酶PB2亚基的一类创新药
【机构调研记录】摩根士丹利基金调研众生药业、东威科技
证券之星 · 05-18
【机构调研记录】摩根士丹利基金调研众生药业、东威科技
众生药业:ZSP1601片是治疗MASH首创一类创新药
证券之星 · 05-14
众生药业:ZSP1601片是治疗MASH首创一类创新药
加载更多
公司概况
公司名称:
广东众生药业股份有限公司
所属行业:
医药制造业
上市日期:
2009-12-11
主营业务:
广东众生药业股份有限公司的主营业务是药品研发、生产和销售。公司的主要产品是昂拉地韦片、来瑞特韦片、复方血栓通系列产品、脑栓通胶囊、复方丹参片、众生丸系列产品、清热祛湿颗粒、羧甲司坦口服溶液(片)、盐酸氨溴索口服溶液、头孢克肟分散片、头孢拉定胶囊、异烟肼片、吡嗪酰胺片、盐酸乙胺丁醇片、利福平胶囊、利巴韦林片、硫糖铝口服混悬液、瑞巴派特片、奥美拉唑肠溶胶囊、盐酸氮䓬斯汀滴眼液、普拉洛芬滴眼液、地夸磷索钠滴眼液、环孢素滴眼液(III)、氯雷他定片、富马酸氯马斯汀口服溶液。
发行价格:
55.00
{"stockData":{"symbol":"002317","market":"SZ","secType":"STK","nameCN":"众生药业","latestPrice":23.3,"timestamp":1782279471000,"preClose":22.89,"halted":0,"volume":37995418,"delay":0,"changeRate":0.0179,"floatShares":762000000,"shares":850000000,"eps":0.3447,"marketStatus":"交易中","change":0.41,"latestTime":"06-24 13:37:51","open":22.72,"high":23.58,"low":22.56,"amount":884000000,"amplitude":0.0446,"askPrice":23.3,"askSize":52,"bidPrice":23.29,"bidSize":194,"shortable":0,"etf":0,"ttmEps":0.3447,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1782284400000},"marketStatusCode":2,"adr":0,"adjPreClose":22.89,"symbolType":"stock","openAndCloseTimeList":[[1782264600000,1782271800000],[1782277200000,1782284400000]],"highLimit":25.18,"lowLimit":20.6,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":849930477,"isCdr":false,"pbRate":4.68,"roa":"--","peRate":67.59501,"roe":"2.43%","epsLYR":0.33,"committee":0.259947,"marketValue":19803000000,"turnoverRate":0.0499,"status":0,"floatMarketCap":17746000000},"requestUrl":"/m/hq/s/002317","defaultTab":"news","newsList":[{"id":"2644470697","title":"众生药业涨9.99%,开源证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2644470697","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644470697?lang=zh_cn&edition=full","pubTime":"2026-06-18 16:40","pubTimestamp":1781772050,"startTime":"0","endTime":"0","summary":"今日众生药业涨9.99%,收盘报22.9元。2026年4月30日,开源证券研究员余汝意,巢舒然发布了对众生药业的研报《公司信息更新报告:2025年经营业绩稳健提升,创新布局赋能发展》,该研报对众生药业给出“买入”评级。此外,东海证券研究员杜永宏,付婷,华鑫证券研究员胡博新近期也对该股发布了研报,同样给出“买入”评级。众生药业个股概况:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800028878.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002317","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644170386","title":"6月18日众生药业(002317)涨停分析:减肥药、MASH创新药、流感药驱动","url":"https://stock-news.laohu8.com/highlight/detail?id=2644170386","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644170386?lang=zh_cn&edition=full","pubTime":"2026-06-18 15:41","pubTimestamp":1781768485,"startTime":"0","endTime":"0","summary":"证券之星消息,众生药业6月18日涨停收盘,收盘价22.9元。6月18日众生药业涨停的可能因素有:RAY1225减肥药II期临床数据亮眼,亮相ADA大会并完成III期入组;ZSP1601治疗MASH的IIb期顶线数据积极,疗效显著优于安慰剂;昂拉地韦颗粒获CDE优先审评,儿童流感适应症进展顺利;公司2025年扭亏为盈、2026Q1净利润同比增20.83%,创新药管线加速兑现。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800022267.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1574","BK0077","002317","06978","BK1161","159992","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644951744","title":"众生药业(002317)披露使用闲置自有资金进行委托理财的进展公告,6月17日股价下跌4.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2644951744","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644951744?lang=zh_cn&edition=full","pubTime":"2026-06-17 22:13","pubTimestamp":1781705597,"startTime":"0","endTime":"0","summary":"截至2026年6月17日收盘,众生药业报收于20.82元,较前一交易日下跌4.71%,最新总市值为176.96亿元。近日,广东众生药业股份有限公司发布《关于使用闲置自有资金进行委托理财的进展公告》。公告显示,公司于2026年6月16日使用控股子公司众生睿创3,000万元闲置自有资金购买东莞银行结构性存款产品,产品期限为71天,起息日为2026年6月18日,到期日为2026年8月28日,预期年化收益率为1.10%至1.70%,产品类型为保本浮动收益型。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061700042091.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0077","BK0239","002317"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644716552","title":"众生药业:昂拉地韦片是全球首款靶向甲型流感病毒RNA聚合酶PB2亚基的一类创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2644716552","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644716552?lang=zh_cn&edition=full","pubTime":"2026-06-17 15:21","pubTimestamp":1781680867,"startTime":"0","endTime":"0","summary":"证券之星消息,众生药业(002317)06月17日在投资者关系平台上答复投资者关心的问题。投资者提问:已经26年6月中旬了,昂拉地韦片25年销量数据还没有公布,需要讳莫如深吗?还是害怕像新冠特效药那样?众生药业回复:您好!昂拉地韦片是全球首款靶向甲型流感病毒RNA聚合酶PB2亚基的一类创新药,适用于成人单纯性甲型流感患者的治疗,销售与流感季节性相关。公司正持续推进学术推广与渠道建设,后续将结合流感周期与医保落地效应,稳步推动昂拉地韦片的商业化工作。谢谢!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:陈思雨","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061700020366.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1574","BK0077","002317","06978","BK1161","159992","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642591282","title":"众生药业:RAY1225注射液表现出积极的疗效和优秀的安全性","url":"https://stock-news.laohu8.com/highlight/detail?id=2642591282","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642591282?lang=zh_cn&edition=full","pubTime":"2026-06-11 20:53","pubTimestamp":1781182382,"startTime":"0","endTime":"0","summary":"RAY1225注射液是具有全球自主知识产权的创新结构多肽药物,具有GLP-1受体和GIP受体双重激动活性,得益于优异的药代动力学特性,具备每两周注射一次的超长效药物潜力,临床上拟用于2型糖尿病及肥胖/超重等患者的治疗。目前,公司正积极推进RAY1225注射液的III期临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061100036137.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002317","BK0188","BK0077","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642564282","title":"众生药业:RAY1225注射液III期临床试验于2025年7月完成入组工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2642564282","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642564282?lang=zh_cn&edition=full","pubTime":"2026-06-11 20:52","pubTimestamp":1781182379,"startTime":"0","endTime":"0","summary":"投资者提问:RAY1225三期减肥超重试验是什么时候全部完成入组的?RAY1225注射液用于治疗中国肥胖/超重患者的安全性和有效性的III期临床试验于2025年7月完成入组工作,试验周期为52周。公司正积极推进RAY1225注射液的III期临床试验,公司将严格根据信息披露规则及时履行信息披露义务,具体请以公司发布的公告为准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061100036135.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","002317","BK0239","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642282550","title":"众生药业:公司积极推进与监管部门的沟通","url":"https://stock-news.laohu8.com/highlight/detail?id=2642282550","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642282550?lang=zh_cn&edition=full","pubTime":"2026-06-11 20:52","pubTimestamp":1781182378,"startTime":"0","endTime":"0","summary":"证券之星消息,众生药业(002317)06月11日在投资者关系平台上答复投资者关心的问题。投资者提问:ZSP1601二期顶线数据出来一个月了,为什么三期还没有进展,遇到什么困难了吗?现在有企业有谈ZSP1601 的BD意向吗?众生药业回复:您好!公司积极推进与监管部门的沟通,并基于本次ZSP1601片IIb期临床试验结果,推进ZSP1601片III期临床试验。同时,公司高度重视药品的海外市场机会,积极寻求国际合作。有关ZSP1601片的具体进展请以公司公告为准。谢谢!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061100036133.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002317","BK0239","BK0077","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640913380","title":"众生药业:积极参与美国糖尿病协会科学年会会议","url":"https://stock-news.laohu8.com/highlight/detail?id=2640913380","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640913380?lang=zh_cn&edition=full","pubTime":"2026-06-04 09:03","pubTimestamp":1780534999,"startTime":"0","endTime":"0","summary":"证券之星消息,众生药业(002317)06月03日在投资者关系平台上答复投资者关心的问题。投资者提问:公司2025年收到美国糖尿病协会邀请,并在大会上以壁报形式展示自主研发的新药RAY1225,公司今年会参加美国糖尿病协会年会吗?众生药业回复:您好!公司始终关注行业交流机会,积极参与美国糖尿病协会科学年会会议,并将围绕创新成果与合作机遇展开深度交流与分享,助力公司完善国际化布局,加速创新成果的转化与共享。谢谢!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060400005116.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002317","BK0188","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640915174","title":"众生药业(002317.SZ):昂拉地韦颗粒纳入优先审评品种名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2640915174","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640915174?lang=zh_cn&edition=full","pubTime":"2026-06-02 16:32","pubTimestamp":1780389142,"startTime":"0","endTime":"0","summary":"智通财经APP讯,众生药业(002317.SZ)发布公告,近日,根据国家药品监督管理局药品审评中心(简称“CDE”)发布的公示信息,公司控股子公司广东众生睿创生物科技有限公司(简称“众生睿创”)自主研发的创新药物昂拉地韦颗粒被CDE纳入优先审评品种名单。CDE对纳入优先审评审批程序的药品上市许可申请,按注册申请受理时间顺序优先配置资源进行审评。该药品拟定适应症:用于2至12岁以下单纯型甲型流感儿童患者的治疗,不包括存在流感相关并发症高风险的患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1449055.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0077","002317","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638695161","title":"众生药业:ZSP1601片Ib/IIa期临床试验结果已发表在自然杂志子刊《Nature Communications》","url":"https://stock-news.laohu8.com/highlight/detail?id=2638695161","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638695161?lang=zh_cn&edition=full","pubTime":"2026-05-28 20:51","pubTimestamp":1779972703,"startTime":"0","endTime":"0","summary":"投资者提问:ZSP1601的二期实验数据有没有发表在顶级刊物上?公司ZSP1601片是具有全球自主知识产权、全新作用机制的治疗代谢功能障碍相关脂肪性肝炎首创一类创新药,目前已获得IIb期临床试验的顶线分析数据。ZSP1601片Ib/IIa期临床试验结果已发表在自然杂志子刊《Nature Communications》。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052800041163.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002317","BK0239","BK0188","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638515416","title":"华鑫证券:给予众生药业买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2638515416","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638515416?lang=zh_cn&edition=full","pubTime":"2026-05-28 12:03","pubTimestamp":1779940998,"startTime":"0","endTime":"0","summary":"华鑫证券有限责任公司胡博新近期对众生药业进行研究并发布了研究报告《公司事件点评报告:稳步推进新药研发》,给予众生药业买入评级。 昂拉地韦持续累积优效临床证据 昂拉地韦为全球首款流感RNA聚合酶PB2蛋白抑制剂,靶点差异于奥司他韦和玛巴洛沙韦。最新盈利预测明细如下:该股最近90天内共有5家机构给出评级,买入评级5家;过去90天内机构目标均价为21.66。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052800018882.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","002317"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638574047","title":"众生药业:公司正在积极推进RAY1225注射液的III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2638574047","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638574047?lang=zh_cn&edition=full","pubTime":"2026-05-27 15:04","pubTimestamp":1779865457,"startTime":"0","endTime":"0","summary":"证券之星消息,众生药业(002317)05月26日在投资者关系平台上答复投资者关心的问题。投资者提问:公司的减肥药,糖尿病药物RAY1225三期试验什么时候结束?公司会参加2026年6月初美国糖尿病大会吗?众生药业回复:您好!公司正在积极推进RAY1225注射液的III期临床试验,有关创新药的进展情况请以公司公告为准。公司始终关注行业交流机会,积极参与美国糖尿病协会科学年会会议,并将围绕创新成果与合作机遇展开深度交流与分享,助力公司完善国际化布局,加速创新成果的转化与共享。谢谢!以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052700024462.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","002317","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638574447","title":"众生药业:昂拉地韦片是全球首款靶向甲型流感病毒RNA聚合酶PB2亚基的一类创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2638574447","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638574447?lang=zh_cn&edition=full","pubTime":"2026-05-27 15:00","pubTimestamp":1779865244,"startTime":"0","endTime":"0","summary":"证券之星消息,众生药业(002317)05月26日在投资者关系平台上答复投资者关心的问题。投资者提问:已经26年5月底了,怎么还看不到昂拉地韦25年流感季的销量?是否在做数据?众生药业回复:您好!昂拉地韦片是全球首款靶向甲型流感病毒RNA聚合酶PB2亚基的一类创新药,适用于成人单纯性甲型流感患者的治疗,销售与流感季节性相关。公司正持续推进学术推广与渠道建设,后续将结合流感周期与医保落地效应,稳步推动昂拉地韦片的商业化工作。谢谢!以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052700024434.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0188","BK1574","06978","002317","159992","BK0239","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638596451","title":"众生药业:公司立足自身产品优势与研发实力,坚持稳健布局、审慎推进的原则,适时拓展海外市场,加快国际化推进步伐","url":"https://stock-news.laohu8.com/highlight/detail?id=2638596451","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638596451?lang=zh_cn&edition=full","pubTime":"2026-05-26 15:00","pubTimestamp":1779778853,"startTime":"0","endTime":"0","summary":"证券之星消息,众生药业(002317)05月25日在投资者关系平台上答复投资者关心的问题。投资者提问:Zsp1601数据非常牛,公司怎么拓展海外市场?众生药业回复:您好!公司始终重视药品的国外市场机会以及药品海外市场广阔机遇与增长空间。公司立足自身产品优势与研发实力,坚持稳健布局、审慎推进的原则,适时拓展海外市场,加快国际化推进步伐。谢谢!以上内容为证券之星据公开信息整理,不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052600020027.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","002317","BK0239","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638531550","title":"众生药业(002317)披露2025年年度权益分派实施公告,5月25日股价下跌0.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638531550","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638531550?lang=zh_cn&edition=full","pubTime":"2026-05-25 17:36","pubTimestamp":1779701780,"startTime":"0","endTime":"0","summary":"截至2026年5月25日收盘,众生药业报收于23.7元,较前一交易日下跌0.88%,最新总市值为201.43亿元。该股当日开盘23.75元,最高24.35元,最低23.1元,成交额达10.63亿元,换手率为5.9%。近日,众生药业发布《2025年年度权益分派实施公告》。公告显示,公司2025年年度权益分派方案为:以公司总股本849,930,477股为基数,向全体股东每10股派发现金红利2.00元(含税),不送红股,不以公积金转增股本,共计派发现金红利169,986,095.40元。本次分配方案与股东会审议通过的一致。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052500024799.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","002317","BK0239","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637874681","title":"【机构调研记录】惠升基金调研众生药业","url":"https://stock-news.laohu8.com/highlight/detail?id=2637874681","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637874681?lang=zh_cn&edition=full","pubTime":"2026-05-21 08:01","pubTimestamp":1779321706,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及5月20日披露的机构调研信息,惠升基金近期对1家上市公司进行了调研,相关名单如下:1)众生药业 个股亮点:公司深度融合互联网技术与创新商业模式,打造精准化医疗解决方案,面向医务工作者提供智能化诊疗支持。旗下最近一年表现最佳的公募基金产品为惠升惠远回报混合A,最新单位净值为1.29,近一年增长63.21%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100007554.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002317","BK0239","BK0077","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637245858","title":"股市必读:众生药业(002317)5月20日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2637245858","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637245858?lang=zh_cn&edition=full","pubTime":"2026-05-21 01:08","pubTimestamp":1779296891,"startTime":"0","endTime":"0","summary":"截至2026年5月20日收盘,众生药业报收于24.52元,上涨3.94%,换手率9.68%,成交量73.7万手,成交额18.05亿元。来自公司公告汇总:众生药业2025年度股东会于2026年5月20日召开,审议通过利润分配预案、续聘审计机构、为子公司提供担保额度及董事高管薪酬相关议案,会议被认定为合法有效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100001690.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0077","002317","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636847667","title":"众生药业:昂拉地韦片是全球首款靶向甲型流感病毒RNA聚合酶PB2亚基的一类创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2636847667","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636847667?lang=zh_cn&edition=full","pubTime":"2026-05-20 20:53","pubTimestamp":1779281599,"startTime":"0","endTime":"0","summary":"证券之星消息,众生药业(002317)05月20日在投资者关系平台上答复投资者关心的问题。投资者提问:已经26年5月了,怎么看不到贵公司昂拉地韦片25年销量?股民有权知道25年每月销量吗?26年1季度销量能公布吗?众生药业回复:您好!昂拉地韦片是全球首款靶向甲型流感病毒RNA聚合酶PB2亚基的一类创新药,适用于成人单纯性甲型流感患者的治疗,销售与流感季节性相关。公司正持续推进学术推广与渠道建设,后续将结合流感周期与医保落地效应,稳步推动昂拉地韦片的商业化工作。谢谢!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052000041340.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0188","002317","BK1161","159992","06978","BK0239","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636012980","title":"【机构调研记录】摩根士丹利基金调研众生药业、东威科技","url":"https://stock-news.laohu8.com/highlight/detail?id=2636012980","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636012980?lang=zh_cn&edition=full","pubTime":"2026-05-18 08:02","pubTimestamp":1779062541,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及5月15日披露的机构调研信息,摩根士丹利基金近期对2家上市公司进行了调研,相关名单如下:1)众生药业 调研纪要:ZSP1601片IIb期临床试验结果显示,两个剂量组主要疗效终点应率分别为64.9%和57.6%,显著优于安慰剂组的32.5%,且在纤维化改善、肝脏脂肪含量下降及肝酶指标方面均显著改善。安全性良好,不良事件发生率与安慰剂组相当。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800002707.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0251","BK0239","002317","BK0077","688700"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635750938","title":"众生药业:ZSP1601片是治疗MASH首创一类创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2635750938","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635750938?lang=zh_cn&edition=full","pubTime":"2026-05-14 08:48","pubTimestamp":1778719692,"startTime":"0","endTime":"0","summary":"证券之星消息,众生药业05月13日在投资者关系平台上答复投资者关心的问题。请问公司1601非酒精型脂肪肝创新药对酒精性脂肪肝是否具有治疗效果?公司ZSP1601片是具有全球自主知识产权、全新作用机制的治疗代谢功能障碍相关脂肪性肝炎首创一类创新药,为国家重大新药创制项目。公司始终以满足未被满足的临床需求为导向,未来,公司将根据实际情况,综合考虑ZSP1601片的适应症拓展,相关信息请以公司公告为准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051400008417.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","06978","BK0077","BK0239","BK0188","002317","BK1161","159992"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1782279472306,"stockEarnings":[{"period":"1week","weight":0.0476},{"period":"1month","weight":-0.0342},{"period":"3month","weight":0.3105},{"period":"6month","weight":0.1848},{"period":"1year","weight":0.4802},{"period":"ytd","weight":0.2166}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0016},{"period":"3month","weight":0.0444},{"period":"6month","weight":0.037},{"period":"1year","weight":0.2143},{"period":"ytd","weight":0.0346}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"广东众生药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"111004人(较上一季度减少2.61%)","perCapita":"6861股","listingDate":"2009-12-11","address":"广东省东莞市石龙镇西湖工业区信息产业园","registeredCapital":"84993万元","survey":" 广东众生药业股份有限公司的主营业务是药品研发、生产和销售。公司的主要产品是昂拉地韦片、来瑞特韦片、复方血栓通系列产品、脑栓通胶囊、复方丹参片、众生丸系列产品、清热祛湿颗粒、羧甲司坦口服溶液(片)、盐酸氨溴索口服溶液、头孢克肟分散片、头孢拉定胶囊、异烟肼片、吡嗪酰胺片、盐酸乙胺丁醇片、利福平胶囊、利巴韦林片、硫糖铝口服混悬液、瑞巴派特片、奥美拉唑肠溶胶囊、盐酸氮䓬斯汀滴眼液、普拉洛芬滴眼液、地夸磷索钠滴眼液、环孢素滴眼液(III)、氯雷他定片、富马酸氯马斯汀口服溶液。","listedPrice":55},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"众生药业(002317)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供众生药业(002317)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"众生药业,002317,众生药业股票,众生药业股票老虎,众生药业股票老虎国际,众生药业行情,众生药业股票行情,众生药业股价,众生药业股市,众生药业股票价格,众生药业股票交易,众生药业股票购买,众生药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"众生药业(002317)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供众生药业(002317)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}